Rafael Holdings, Inc.
NNYSE:RFLRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Rafael Holdings, Inc. (NYSE:RFL) is a clinical-stage biotechnology holding company that invests in and develops therapies for difficult-to-treat diseases, including novel cancer metabolism inhibitors and treatments for rare genetic disorders; it operates through healthcare, infusion technology, and real estate segments with activities in the United States and Israel. Founded in 2017 and headquartered in Newark, New Jersey, the company holds a 100% interest in Cyclo Therapeutics, LLC, which advances Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin) in the fully enrolled Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1, with 48-week interim data expected mid-2025; it maintains investments in Cornerstone Pharmaceuticals developing CPI-613 (devimistat) for solid tumors and acute myeloid leukemia, LipoMedix Pharmaceuticals with liposome-delivered oncology therapies, Day Three Labs reimagining cannabis products via pharmaceutical-grade technology like Unlokt, Rafael Medical Devices for orthopedic instruments, and commercial real estate assets. In March 2025, Rafael Holdings completed its merger with Cyclo Therapeutics following shareholder approval, integrating the rare disease asset and shifting strategic focus toward its commercialization while curtailing early-stage development; the company closed a $25 million rights offering in June 2025 to fund Trappsol Cyclo advancement, issued 1,078,796 warrants expiring December 2025 as part of the merger, and announced CEO Bill Conkling's transition amid strengthened emphasis on Trappsol Cyclo, with recent abstracts accepted for presentation at the 15th International Congress of Inborn Errors of Metabolism and preliminary Phase 3 sub-study data showing stabilization in young NPC1 patients.
Company News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
Rafael's Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing
Aetna 2027 Medicare plans offer reliable, affordable access to care & member support
Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development
Head to Head Comparison: Oncology Pharma (OTCMKTS:ONPH) & Rafael (NYSE:RFL)
Manhattan Uranium Identifies High-Grade Uranium Intercepts from 5,668-Hole Database Compilation at I-70, San Rafael District, Utah
Sekur Private Data Appoints Special Operations Communications Chief Master Sergeant (Ret.) Rafael Beltran to Its OpsTech Special Advisory Board
AuMEGA Metals Appoints Rafael Gradim as President
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever
Heineken names Rafael Oliveira as CEO
Heineken N.V. announces nomination of Rafael Oliveira as Chief Executive Officer
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C